Gadolinium based contrast agents (GBCA) play a critical role in identifying MS lesions undergoing BBB which is of high clinical importance. However, repeated use of GBCAs over a long period of time and the risks associated with administering it to patients with renal complications has mandated for greater caution in its usage. In this work we explored the plausibility of identifying MS lesions undergoing BBB from tissue microstructure information obtained from T2 relaxometry and dMRI data. We also proposed a framework to predict MS lesions undergoing BBB using the tissue microstructure information and demonstrated its potential on a test case.